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the CC BY-NC-ND license (http://creaAbstract Although multiple advances have been made in systemic therapy for renal cell car-
cinoma (RCC), metastatic RCC remains incurable. In the current review, we focus on the un-
derlying biology of RCC and plausible mechanisms of metastasis. We further outline evolving
strategies to combat metastasis through adjuvant therapy. Finally, we discuss clinical patterns
of metastasis in RCC and how distinct systemic therapy approaches may be considered based
on the anatomic location of metastasis.
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Approximately one-third of patients with renal cell carci-
noma (RCC) present with metastatic disease, and amongst
those patients with localized disease, a substantial pro-
portion will recur [1]. For patients with metastatic renal. Pal).
of Second Military Medical
to this work.
.08.006
sian Journal of Urology. Producti
tivecommons.org/licenses/by-nc-cell carcinoma (mRCC), the landscape of therapy has
evolved dramatically over the past decade. Prior to 2005,
immunotherapy represented the mainstay of therapy with
agents such as interleukin-2 (IL-2) and interferon-a (IFN-a)
[2,3]. Estimates of overall survival (OS) in that era coa-
lesced around 1 year. Since 2005, multiple targeted ther-
apies have been approved, primarily directed at vascular
endothelial growth factor (VEGF) or its cognate receptor
(VEGF receptor, or VEGFR), or the mammalian target of
rapamycin (mTOR) [4]. In this generation of therapies, in-
hibitors of VEGF include axitinib, bevacizumab, pazopanib,
sorafenib and sunitinib, while inhibitors of mTOR includeon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
RCC metastasis 287everolimus and temsirolimus [5e10]. These agents have
collectively improved median survival estimates to
approximately 2.5e3 years [11]. Over the past year, 3
additional FDA approvals have been granted for mRCC for a
VEGFR/MET/AXL inhibitor (cabozantinib), a programmed
death-1 (PD-1) inhibitor (nivolumab) and a multikinase in-
hibitor (lenvatinib, approved with everolimus) [12e14]. It
remains to be seen how these agents will alter OS estimates
for mRCC, although it will surely move the bar in a positive
direction.
Despite these critical advances, the reality is that the
vast majority of patients with mRCC have incurable disease
[15]. A goal of treatment is to maximize the yield of existing
systemic therapies through personalized approaches. In the
current review, we explore how clinical and biological
properties of metastases may potentially alter paradigms
for systemic therapy.
2. Biology of RCC
2.1. Differing biology by histology
It is critical to acknowledge that mRCC is comprised of mul-
tiple distinct histologies, each with unique biologic un-
derpinnings. The most common histology is clear cell,
comprising 75%e80% of cases. Approximately 70% of patients
with clear cell RCC bear alterations in the Von-Hippel Lindau
(VHL) gene [16]. Wild type VHL protein functions as an ubiq-
uitin ligase, participating in degradation of hypoxia inducible
factor (HIF). In patients bearing VHL alteration, the resulting
high levels of HIF result in upregulation of VEGF. VEGF acti-
vates VEGFR, triggering the phosphoinositol-3-kinase (PI3K)-
Akt signaling cascade. Downstream, mTOR is activated and
leads to transcriptionof a varietyof tumor-promoting factors,
resulting in increased cellular migration and angiogenesis.
Although VEGFR has typically been implicated as the key
driver of tumor progression in RCC, there is emerging evi-
dence that other transmembrane receptors may potentially
drive metastasis, including MET and AXL [17].
Non-clear cell RCC histologies comprise roughly 20%e25%
of patients overall. The most prevalent of these is papillary
RCC, which represents 10%e15% of patients. Papillary RCC is
frequently subdivided into type I and type II disease. Type I
disease is characterized by alterations in the MET proto-
oncogene, while type II is characterized by a variety of al-
terations. Recent data from The Cancer Genome Atlas
(TCGA) investigators highlighted alterations in SETD2,
CKDN2A and TFE3 fusions as frequent events in type II
papillary RCC [18]. Chromophobe type disease comprises
approximately 5% of all RCC cases. TCGA data pertaining to
chromophobe RCC suggest frequent changes in the TERT
promoter region, and mitochondrial DNA analyses suggest
changes in mitochondrial function [19]. Beyond papillary and
chromophobe RCC, other histologies of RCC represent<1% of
all cases. Despite their rarity, there are efforts to charac-
terize the genomic changes occurring in these entities. For
instance, our group has identified frequent alterations in NF2
in patients with collecting duct RCC, an exquisitely rare
diagnosis with a dismal prognosis [20].
Admixed with any histological subset of RCC may be
sarcomatoid elements. Sarcomatoid RCC is thought tocoexist with other histologies in about 25% of cases [21].
Sarcomatoid disease tends to be particularly aggressive,
although (as discussed subsequently) the current treatment
paradigm is not distinct from clear cell disease. Our group
has identified frequent alterations in the aurora kinase
pathway, and NF2 alterations have also been detected in
this disease [22,23].
2.2. Tumor heterogeneity
Although histology is frequently used to offer prognostic
data to patients, it is critical to acknowledge that the
biology of tumors may differ across sites of metastasis. One
of the first detailed studies to identify this intratumoral
heterogeneity was from Gerlinger and colleagues [24]. In
an effort that included just 4 patients with mRCC, separate
sites of metastasis were evaluated. Alterations in the
mTOR pathway were variable across sites of metastasis, as
were alterations in SETD2, PTEN and KDM5C. Subsequent
sections will highlight potential therapeutic strategies for
these alterations. With the evolution of novel immuno-
therapeutic strategies, there has also been substantial
interest in characterizing PD-L1 expression in metastatic
sites. A recent study from the Dana Farber Cancer Institute
compared tissues derived from 53 primary RCC specimens
and 73 corresponding metastases [25]. PD-L1 expression
appeared to be consistent, although PD-L1 expression was
noted to be heterogeneous within lesions.
2.2.1. Biological mediators of metastasis
Little is agreed upon regarding the biological mechanisms
that drive RCC metastasis. On a macromolecular level,
Grange et al. [26] have proposed that tumor-derived
microvesicles (which essentially break off from the pri-
mary site) may disperse tumors through hematogenous
routes. These microvesicles appear to bear CD105-positive
cells, which carry a cancer stem cell phenotype, and
microRNAs which stimulate angiogenesis. The immune
milieu may also play a critical role in the evolution of
metastases. In preclinical models, neutrophilic infiltration
in the lungs (accompanied by secretion of neutrophil
chemokines) was accompanied by suppression of pulmo-
nary metastases of RCC [27]. In contrast, loss of neutrophil
chemokines in the lung was accompanied by an increase in
pulmonary metastases. Other immune cells with negative
effects on antitumor immunity (e.g., myeloid derived
suppressor cells, or MDSCs) have been shown to have a pro-
angiogenic effect and cause propagation of RCC in pre-
clinical models [28].
Beyond these macromolecular events, several molecular
mediators of RCC metastasis have been identified. In the
setting of clear cell RCC bearing VHL alteration, it has been
proposed that CUB-domain-containing protein (CDCP1) may
drive metastasis [29]. CDCP1 is regulated through HIF
dependent pathways and drives activation of protein kinase
C-d (PKCd), which in turn increases cellular migration.
Expression of MUC1, a membrane-bound glycoprotein, is
also HIF-dependent, and knockdown of MUC1 has been
shown to markedly decrease cellular invasion and migration
in in vitro RCC models [30]. Various chemokine receptors,
including CXCR4, also appear to be upregulated in the
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and its ligand CXCL12 in the setting of VHL alteration has
been associated with increased metastatic spread in pre-
clinical studies [31].
3. Prevention of tumor metastasis: role of
adjuvant therapy
3.1. Localized disease
At present, there is no defined role for adjuvant therapy for
localized RCC following partial or radical nephrectomy. The
current standard of care involves serial imaging with
computerized tomography, typically up to a span of 5 years.
However, multiple trials have evaluated the strategy of
using approved agents in the metastatic setting as adjuvant
therapy [32]. Both adjuvant VEGF-tyrosine kinase inhibitors
(VEGF-TKIs) and mTOR inhibitors have been evaluated,
including sunitinib, sorafenib, pazopanib, axitinib and
everolimus.
The first phase III study to report out exploring adjuvant
therapy is the phase III ASSURE trial [33]. This study ran-
domized 1943 patients to receive one of two VEGF-TKIs
(sunitinib or sorafenib) or placebo. The study had to be
modified on the basis of early toxicity events; in a modifi-
cation to the original design, patients were started on a
lower dose of sunitinib and sorafenib. Doses were escalated
if no toxicities were incurred after a 2-month period. The
primary endpoint of the study was disease-free survival,
and the trial identified no significant difference across the
three cohorts (5.8 years with sunitinib, 6.1 years with sor-
afenib and 6.6 years with placebo). Aside from failing to
meet the primary endpoint of the study, there were also
concerns regarding treatment related toxicity. Toxicities
encountered were typical for VEGF-directed therapies,
with the most common adverse events being hypertension,
hand-foot syndrome, rash and fatigue. A total of five deaths
occurred within the first month of protocol-based therapy.
Four of these patients had received sunitinib, with deaths
attributable to neurologic dysfunction, gastrointestinal
perforation, pulmonary embolus and disease progression,
respectively. The remaining patient received sorafenib and
developed infectious colitis during therapy. In the adjuvant
setting, even if a modest benefit with adjuvant therapy was
observed, it would need to be counterbalanced against the
toxicity profile and the potential risk of treatment-related
mortality.
The remaining trials of adjuvant targeted therapy in RCC
have yet to report out. Each of these studies includes a
slightly different patient population and treatment strat-
egy, and thus, it is possible that the results may differ from
the aforementioned ASSURE trial (Table 1). For instance,
the phase III ATLAS study compares a total of 3 years of
axitinib therapy to placebo, and the phase III SORCE study
similarly examines 3 years of adjuvant sorafenib. The phase
III EVEREST trial uniquely explores the mTOR inhibitor
everolimus e it is possible that the increased tolerability of
mTOR inhibition may make enhance adherence and dose
intensity. Although ASSURE is the first study to report final
results, data from the phase III S-TRAC trial are anticipated
shortly. A recent press release suggested that this trial (acomparison of 1 year of adjuvant therapy with sunitinib to
placebo) met its primary endpoint of improved disease-free
survival [34]. The study differed from ASSURE in that it
included a higher risk population. Specifically, while
ASSURE allowed enrollment of patients with pT1b and grade
3e4 disease, or pT2-4 disease and any grade, S-TRAC
enrollment was limited to patients with pT3-4 disease with
any grade. The study included just over 670 patients, a
sample size considerably smaller than ASSURE.
It is curious that S-TRAC would yield a positive result. A
subset analysis of the ASSURE study limited to pT3-4 pa-
tients still failed to show a benefit in disease-free survival,
despite including a sample size comparable to the overall S-
TRAC study population. Subtle differences such as radio-
graphic interpretation may potentially account for the
discordant results e S-TRAC employed central radiographic
review, while local review was performed in the ASSURE
trial. In any case, the implementation of results from S-
TRAC will likely be contingent on a number of factors as yet
unknown, including the magnitude of benefit with adjuvant
sunitinib in this study and the degree of toxicity incurred.
Beyond VEGF- and mTOR-inhibitors, the favorable
toxicity profile of PD-1 inhibitors makes these agents
attractive for use in the adjuvant setting. Furthermore, as
previously noted, studies have shown relatively balanced
expression of PD-L1 in both primary tumor and metastases.
The Eastern Cooperative Oncology Group (ECOG) has un-
veiled a plan for assessing both neoadjuvant and adjuvant
therapy with nivolumab in a phase III clinical trial. Other
agents such as atezolizumab, a PD-L1 inhibitor, may soon be
explored in this setting.
3.1.1. Metastatic disease
Metastasectomy is the standard of care for patients who
have limited sites of metastasis from RCC. There are
limited adjuvant studies that incorporate patients who
have had metastasectomy for stage IV RCC e ostensibly,
these patients carry the highest potential risk of recur-
rence, with some retrospective series suggesting a median
time to recurrence as low as 16 months [35]. The standard
of care in this setting is vigilant observation e although no
guidelines exist, monitoring every 3 months with comput-
erized tomography represents a reasonable practice. ECOG
2810 is a prospective, phase III study randomizing patients
with fully resected clear cell mRCC to either pazopanib or
placebo for 1 year. The study will accrue a total of 126
patients. Previous trials of adjuvant therapy, such as
ASSURE, have been criticized for inclusion of low-risk pa-
tients, which thereby increases the necessary effect size
for any intervention. The high risk of recurrence in the
ECOG 2810 study population may poise the trial well for a
positive outcome.
4. Patterns of metastases in RCC
One of the most widely cited studies of RCC metastasis
distribution is derived from the National Inpatient Sample
[36]. In this study, 11,157 patients with mRCC were iden-
tified from 1998 to 2007. The most common sites of me-
tastases were lung (45%), following by bone (30%) and
lymph node (22%). Liver metastases were noted in 20% of
Table 1 Trials of adjuvant targeted therapy in RCC.
Trial (sponsor) Randomization Treatment
duration
(year)
n Limited to
clear cell
Inclusion criteria Details
Reported trials
ASSURE (ECOG) Sunitinib vs. sorafenib vs.
placebo
1 1943 No pT1b (G3-4) or
pT2-4 or Nþ
 Study showed no signifi-
cant difference in DFS
across arms
S-TRAC (Pfizer) Sunitinib vs. placebo 1 670 Yes pT3-4 or Nþ  Press release indicates
study met primary
endpoint
 Further study results to be
presented at upcoming
meeting
Unreported trials
ATLAS (Pfizer) Axitinib vs. placebo 3 592 Yes pT2-4 or Nþ  Study employs a longer
duration of axitinib
therapy
 Small sample size relative
to other adjuvant trials
EVEREST (SWOG) Everolimus vs. placebo 1 1218 No pT1b (G3-4) or
pT2-4 or Nþ
 Study nearing completion
of accrual
 Only adjuvant trial to
assess an mTOR inhibitor
PROTECT (GSK) Pazopanib vs. placebo 1 1500 Yes pT1b (G3-4) or
pT2-4 or Nþ
 Projected accrual per arm
(n Z 750) makes this the
most sizeable exploration
of a VEGF-TKI in a single
study
SORCE (MRC) Sorafenib vs. placebo 3 1420 No Leibovich
score 3-11
 Only study to utilize Lei-
bovich scoring criteria
 Leibovich scoring utilizes
pathologic elements such
as tumor necrosis, which
are subject to variability
amongst reviewers
ECOG, Eastern Cooperative Oncology Group; DFS, disease-free survival; mTOR, mammalian target of rapamycin; GSK, GlaxoSmithKline;
VEGF-TKI, vascular endothelial growth factor tyrosine kinase inhibitor; MRC, Medical Research Council; RCC, renal cell carcinoma.
RCC metastasis 289patients and adrenal metastases were noted in 9% of pa-
tients. Brain metastases occurred in approximately 9% of
patients (Fig. 1).
Several series have pointed towards distinct outcomes
depending on patterns of metastasis. In an assessment of
2027 mRCC patients from the International mRCC Database
Consortium (IMDC) experience, liver metastases were
noted to occur in a larger proportion of patients with poor-
risk by IMDC criteria [37]. Furthermore, the hazard ratio
for death (adjusted for IMDC risk factors) was 1.4 for pa-
tients with bone metastases (95%CI 1.22e1.62) and 1.42 for
patients with liver metastases (95%CI 1.17e1.73). IMDC
data have also been used to assess the outcome of patients
with brain metastases [38]. Approximately 106 patients
were identified with brain metastases, of which only 12%
fell into the favorable IMDC risk group. Most patients (90%)
had cerebral metastases, while a smaller subset (17%) had
cerebellar metastases. As one might anticipate, a higher
number of brain metastases were associated with poorer
outcome.There are several sites of metastases that are associated
with more favorable prognoses. Multiple anecdotal reports
exist documenting regression of lung metastases following
either brief local or systemic therapy for mRCC, and
broadly, patients with lung-only metastases are thought to
carry a favorable prognosis [39e41]. Interestingly, pancre-
atic metastases are also thought to confer a favorable
prognosis. In a retrospective series from MD Anderson, 228
patients with pancreatic metastases were characterized.
Median OS was 39 months in patients with pancreatic me-
tastases as compared to 26 months in patients without
(p < 0.010).
5. Treatment by anatomic site
5.1. Bone metastases
While a comprehensive discussion of RCC treatment options is
beyond the scope of this review, we discuss herein unique
Figure 1 Unique considerations for sites of metastasis in mRCC. IL-2, interleukin-2; IMDC, International mRCC Database Con-
sortium; mRCC, metastatic renal cell carcinoma; OS, overall survival; VEGF-TKIs, VEGF-tyrosine kinase inhibitors.
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anatomic sites. In particular, bone and brain metastases
represent significant therapeutic dilemmas. For patientswith
bone metastases, recent data have alluded to the potential
utility of cabozantinib. Cabozantinib, a multikinase inhibitor
with activity against VEGFR, MET and AXL, has previously
been demonstrated to have impressive activity in bone me-
tastases derived from prostate cancer. In this setting, disap-
pearance of lesions on bone scan has been observed [42]. In
mRCC, cabozantinib was compared to everolimus in a phase
III clinical trial, demonstrating an improvement in progres-
sion-free survival (PFS), response rate and OS [14]. In the
overall study population, progression-free survival (PFS) was
7.4 months with cabozantinib versus 3.9 months with ever-
olimus (p < 0.001). Subset analyses of patients with bone
metastases show persistence of this PFS benefit (7.4 months
with cabozantinib vs. 2.7 months with everolimus) [43].
Cabozantinib was also noted to exert a greater reduction in
markers of bone turnover, such as N-telopeptide.
5.2. Brain metastases
As noted previously, brain metastases occur in roughly 9% of
patients with mRCC. The central nervous system (CNS) is
thought to represent a sanctuary site for RCC; preclinical
studies show incomplete penetration with agents such as
sunitinib and sorafenib [44]. For front-line therapy, the
pivotal phase III study of temsirolimus did permit patients
with brain metastases e a distinction from previously pub-
lished front-line trials of VEGF-directed therapies. In pa-
tients with mRCC and poor-risk features, temsirolimus was
compared to IFN-a and the combination of both agents.
Treatment with temsirolimus monotherapy led to animprovement in OS as compared to IFN-a. Although subset
analyses pertaining to patients with brain metastases are
not available, the inclusion of this subpopulation provides
some justification for offering temsirolimus front-line.
There have been retrospective reviews assessing the
safety and efficacy of VEGF-TKIs in mRCC with brain metas-
tasis. In one single institution study, 65 patients with brain
metastases from mRCC were identified. The preponderance
(80%) received VEGF-directed therapy front-line with a very
limited number of neurologic adverse events. In total,
neurologic adverse events were noted in five patients, and
included radiation necrosis and brainmetastasis hemorrhage.
In the second-line setting, the current clinical debate
surrounds use of either cabozantinib or nivolumab. Like
cabozantinib, nivolumab was assessed in a phase III com-
parison against everolimus in patients with prior VEGF-
directed therapy [12]. Nivolumab was noted to improve
both OS and response rate as compared to everolimus.
However, it is worthy to note that the phase III assessment
of nivolumab did not include patients with brain metasta-
ses, while the phase III assessment of cabozantinib did.
Thus, in the second-line setting, cabozantinib may be the
preferred approach for patients with CNS disease.
6. Conclusion
An understanding of the biology of RCC metastasis will most
surely drive advances in systemic therapy in both the
adjuvant and metastatic setting. As noted herein, there are
multiple studies that are currently addressing the potential
role of VEGF- and mTOR-inhibitors as adjuvant treatment.
This is a derivative approach based on the observed activity
of these agents in the metastatic setting. Although the
RCC metastasis 291majority of adjuvant studies have yet to report, the
emerging data from the S-TRAC and ASSURE studies (both
exploring VEGF-TKIs) have produced contrasting results.
Cautious interpretation of the data will surely be necessary
before these approaches are implemented clinically. The
potential interplay of immune cells in generating metas-
tases might prompt speculation that adjuvant PD-1 or PD-L1
inhibition could be feasible as adjuvant treatment. These
studies will likely be emerging in the near future.
Once RCC does spread, it is critical to note that varying
sites of metastasis may carry distinct implications for
prognosis. While patients with bone, liver and brain me-
tastases may carry an inferior prognosis relative to the
overall population of mRCC patients, patients with
pancreatic metastases may have a superior prognosis. At
present, there is insufficient evidence to take a tailored
approach for each metastatic site. Subset analyses from
phase III studies do afford an opportunity to understand the
relative benefit of systemic agents in unique settings (e.g.,
cabozantinib in bone metastases). Furthermore, review of
eligibility criteria from these phase III studies do allow
the practicing clinician to understand the applicability of
data d for instance, patients with brain metastases were
not consistently permitted entry in front-line trials. Pro-
spective studies that assess these unique populations may
ultimately provide the most relevant insights.
Many gaps remain in our understanding of RCC metas-
tasis. For instance, although the distinct biology of RCC
histologies was acknowledged, we have little sense of how
this might affect patterns of metastasis. The varied clinical
outcomes for different histological subtypes certainly un-
derscores that each may progress through distinct mecha-
nisms. Furthermore, although much emphasis has been
placed on optimizing treatment of disease at certain
anatomic sites (e.g., bone and brain metastases), it would
be helpful to know if other sites of metastases (e.g.,
pancreatic metastases, adrenal metastases and so on)
progress through distinct mechanisms. A better biological
understanding of these clinical circumstances will move us
towards the goal of personalizing therapy across these
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